Boston Scientific Corporation / Vertiflex, Inc.

Lumbar Spinal Stenosis

$60M Superion 2019 expected sales (US)

Disease Overview

Lumbar spinal stenosis (LSS) is a degenerative narrowing of the spinal canal that compresses nerves and produces pain, numbness and cramping in the legs (neurogenic claudication). It primarily affects older adults, is the leading cause of spinal surgery in patients over 65, and conservative therapy (PT, epidural steroids) often fails before patients face decompression surgery.

Competitive Landscape

The LSS treatment continuum runs from conservative care (NSAIDs, PT, epidural steroid injections) to minimally invasive procedures and ultimately open laminectomy or fusion. Vertiflex's Superion is the only FDA-approved stand-alone interspinous spacer in the US after Medtronic's X-STOP was withdrawn over migration and failure-rate concerns; head-to-head data showed Superion outperforming X-STOP across complication metrics. Its primary minimally invasive competitor is Vertos Medical's MILD (Minimally Invasive Lumbar Decompression) procedure, used by overlapping interventional pain physicians, with both sitting upstream of surgical fusion options from Medtronic, Stryker, and NuVasive. For Boston Scientific, the deal slots Superion into its Pain Management franchise alongside Spectra WaveWriter and Precision spinal cord stimulators, giving pain specialists a non-stimulator option earlier in the treatment algorithm. Wells Fargo's Larry Biegelsen flagged Superion's appeal as a pre-surgical referral tool. The deal effectively consolidates the standalone interspinous spacer category under a strategic owner with sales reach into pain clinics and ambulatory centers.